Introduction
============

Head and neck squamous cell carcinomas (HNSCCs) are a heterogeneous group of diseases with a biologically aggressive nature. Palliative chemotherapy remains the standard of care treatment in the metastatic setting, and it is associated with modest response and, in general, poor prognosis. The current molecular classification discerns only the human papillomavirus (HPV)-positive and HPV-negative HNSCCs. Beyond HPV status, the lack of predictive biomarkers remains a major obstacle in the treatment of the disease.[@b1-ott-9-705]

Recently, extensive efforts have been made to incorporate molecular information in order to underpin the molecular driver of the disease, guide treatment decision, and predict outcome. By deciphering the mechanisms of response to targeted therapy, comprehensive genomic profiling of exceptional responders serves as a promising approach that may aid in identifying validated molecular phenotypes of sensitivity to targeted agents that would eventually lead to more effective personalized therapy.[@b2-ott-9-705]

We describe here the clinical course and genomically characterize the tumor profile of a patient with metastatic HNSCC who achieved a unique and durable response to epidermal growth factor receptor (EGFR) monoclonal antibody. Our report illustrates a candidate biomarker that may be associated with improved response to cetuximab monotherapy.

Case report
===========

A 56-year-old woman with a 25-pack-year smoking history and alcohol abuse initially presented with a 12-month history of worsening dysphagia, odynophagia, and unintentional weight loss. Physical examination revealed a hard and fixed right-sided neck mass. Flexible laryngoscopy revealed an asymmetric mass at the base of tongue of which the biopsy was consistent with HPV-negative, moderately differentiated squamous cell carcinoma. Initial 18-fluorodeoxyglucose (FDG) positron emission tomography and computerized tomography (PET/CT) scan revealed an extensive, intensely FDG-avid, right base of tongue lesion and metastatic right upper neck lymphadenopathy with no distant metastasis ([Figure 1A](#f1-ott-9-705){ref-type="fig"}). Definitive concurrent chemoradiation was initiated using high-dose cisplatin. The first chemotherapy cycle was complicated by acute renal injury. Therefore, she was switched to cetuximab and received a loading dose of 400 mg/m^2^ followed by 250 mg/m^2^ weekly concurrently along with radiation treatment (total dose of 70 Gy; 200 cGy/fraction). She experienced a complete metabolic response on restaging PET/CT at 6 months ([Figure 1B](#f1-ott-9-705){ref-type="fig"}). A follow-up PET/CT obtained ∼19 months from the initial PET/CT was consistent with the persistent response in the head and neck region but showed an intense right renal lesion and another less intense lesion on the left kidney ([Figure 1C](#f1-ott-9-705){ref-type="fig"}). Subsequently, she underwent right partial nephrectomy. Surgical pathology confirmed a moderately differentiated metastatic squamous cell carcinoma with morphology very similar to the previously biopsied tongue lesion indicating the metastasis of head and neck origin. Repeat PET/CT scan performed at 22 months revealed a slight progression of the left renal lesion without any evidence of FDG-avid metastatic disease elsewhere ([Figure 1D](#f1-ott-9-705){ref-type="fig"}). She was therefore initiated on palliative cetuximab and achieved complete remission as evidenced by restaging PET/CT 2 months later ([Figure 1E](#f1-ott-9-705){ref-type="fig"}). The patient continued therapy for 4 additional months. Cetuximab was subsequently stopped for 6 months as per patient's preference. Interval PET/CT performed at 36 months showed recurrence in the left kidney ([Figure 1F](#f1-ott-9-705){ref-type="fig"}). Cetuximab was resumed again and she had the resolution of the prior noted left kidney lesion within 3 months after the resumption of the therapy ([Figure 1G](#f1-ott-9-705){ref-type="fig"}). The patient was on intermittent cetuximab therapy with recurrence during break and response during treatment. She eventually underwent stereotactic body radiation therapy to the left kidney lesion 4 years later due to local progression. Maintenance cetuximab was resumed subsequently, and the patient remained on it for 12 additional months, experiencing good local control and good tolerance except for grade 1 mucocutaneous toxicity. Comprehensive multiplatform biomarker analysis performed on the left kidney metastasis discovered EGFR overexpression by immunohistochemistry, PI3K E542K mutation at exon 9, and TP53 C176S mutation at exon 5. Neither PD-1/PD-L1 expression nor RAS and BRAF mutations were detected ([Table 1](#t1-ott-9-705){ref-type="table"}). The patient provided a written informed consent for the treatment. Institutional Review Board approval was not sought as the treatment offered is standard of care and not part of a clinical trial therefore considered exempt from approval by the Institutional Review Board of Louisiana State University Health Sciences Centre in Shreveport.

Discussion
==========

HNSCC is the sixth leading cause of cancer worldwide.[@b1-ott-9-705] Most patients present with advanced disease at the time of diagnosis, with regional nodal involvement in 43% and distant metastasis in 10% of the cases. The most common distant metastatic sites are lung (80%), mediastinal lymph nodes (34%), bone (31%), and liver (31%).[@b3-ott-9-705] Isolated renal metastasis is very rare and only a limited number of cases have been published in the literature.[@b4-ott-9-705]--[@b7-ott-9-705] Amid a complex genetic landscape, metastatic HNSCC carries a very poor prognosis.[@b8-ott-9-705] A better understanding of the molecular driver of the disease is fundamental for an efficacious personalized treatment. Currently, EGFR is recognized as a critical target in the treatment of HNSCC. It is overexpressed in \>90% of HNSCC, and it is associated with a poor prognosis.[@b8-ott-9-705] Cetuximab, a human--murine chimeric immunoglobulin G1 monoclonal antibody, blocks the EGFR after binding to its extracellular domain. The antitumoral activity of cetuximab occurs via various mechanisms: 1) preventing the ligand transforming growth factor alpha and epidermal growth factor from binding to their receptor (EGFR), thus decreasing the receptor activity and subsequently tumor growth;[@b9-ott-9-705] 2) downregulating the number of surface EGFR via their internalization and endosomal degradation;[@b9-ott-9-705] or 3) inducing an immune-mediated response that leads to cancer cell apoptosis. The latter can be the result of direct killing via antibody-dependent cellular cytotoxicity (ADCC) and complement-mediated cytotoxicity, or opsonization of tumor for phagocytosis and subsequent antigen processing by antigen-presenting cells.[@b10-ott-9-705] Of note, ADCC results from the interaction of the Fc portion of the monoclonal antibody (such as cetuximab) with the Fc receptor on the immune cells, primarily natural killer cells and monocytes.

As demonstrated in the EXTREME trial, the addition of cetuximab to platinum-5-fluorouracil doublet significantly improves the response rate and progression-free and overall survival in metastatic HNSCC.[@b11-ott-9-705] Cetuximab when used as a single agent exhibits a cytostatic effect rather than cytotoxic effect, with an objective response rate of only 13%.[@b12-ott-9-705],[@b13-ott-9-705] As per our knowledge, only one previous case described a complete and prolonged response to a single-agent cetuximab in metastatic HNSCC. The tumor was positive for HPV and negative for EGFR expression.[@b14-ott-9-705]

Mechanism-based predictors of response to cetuximab in HNSCC remain incompletely characterized, and the discovery of reliable predictive biomarkers employing genomic and proteomic analysis is paramount. In metastatic non-small cell lung cancer (NSCLC), FLEX trial has shown that the addition of cetuximab to cisplatin and vinorelbine improves the overall survival in the subgroup of patients overexpressing EGFR.[@b15-ott-9-705] On the contrary, the value of EGFR overexpression as biomarker of response to EGFR monoclonal antibody in HNSCC has not been established,[@b8-ott-9-705] In fact, the benefit of adding cetuximab to chemotherapy was observed independently of EGFR expression level. Unlike what is observed in NSCLC, EGFR tyrosine kinase inhibitors have modest clinical efficacy in HNSCC. The discrepancy in the predictive value of EGFR expression along with the differential therapeutic response to a distinct class of EGFR inhibitors may reflect a difference in the dependency to EGFR pathway between HNSCC and NSCLC. Indeed, cetuximab-mediated ADCC may account for the difference in therapeutic activity between tyrosine kinase inhibitor and EGFR monoclonal antibodies in HNSCC and partially explains why biomarkers focused on EGFR expression are not reliable in HNSCC.[@b16-ott-9-705]

Our case supports a cetuximab-dependent immunologic response against the tumor. In our patient, molecular profiling revealed EGFR overexpression. Interestingly, the patient also carries PI3K mutation, known as a mechanism of resistance to EGFR inhibitor through constitutive activation of the downstream EGFR-mediated signaling pathway, AKT/PI3K/mechanistic target of rapamycin, despite the blockage of EGFR.[@b12-ott-9-705],[@b17-ott-9-705] In addition, p53 mutation, a process that renders cancer cells refractory to apoptosis, was found in the tumor, a common finding in HPV-negative HNSCC. The excellent response to cetuximab monotherapy, despite the activation of compensatory escape pathways, can be explained by cetuximab-mediated ADCC rather than EGFR signaling blockage per se.[@b16-ott-9-705] It is very possible that the absence of PD-1 and PD-L1 expression known as negative regulators of the antitumoral immune response has further potentiated the cetuximab-mediated immune response.[@b8-ott-9-705] Therefore, this observation goes along with the concept of synergism between tumor-targeting monoclonal antibody and checkpoint inhibitors, such as PD-1/PD-L1 axis blockers. Building on these observations, this case provides some insight about urgently needed biomarkers that predict response to targeted therapy. Since the majority of patients with recurrent metastatic HNSCC express PD-1 and/or PD-L1,[@b18-ott-9-705] the lack of their expression in the context of EGFR overexpression may define a small subset of patients who can derive clinical benefit from a single-agent cetuximab. Adequate evidence from large genomics databases are required to examine this hypothesis.
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![FDG PET/CT images with upper row showing PET scan sequences and lower row showing respective CT cross-sections.\
**Notes:** (**A**) Initial PET/CT depicting a locally advanced disease upon diagnosis. (**B**) Complete remission following definitive concurrent chemoradiation. (**C**) Appearance of right kidney lesion that turned out to be metastatic squamous cell carcinoma on nephrectomy. (**D**) Appearance of FDG-avid left renal lesion. (**E**) Complete metabolic response in the left kidney after the initiation of cetuximab. (**F**) Relapse in the left kidney after treatment holiday. (**G**) Complete remission again observed after the reinitiation of cetuximab therapy.\
**Abbreviations:** FDG, fluorodeoxyglucose; PET/CT, positron emission tomography and computerized tomography.](ott-9-705Fig1){#f1-ott-9-705}

###### 

Summary of molecular profiling of the recurrent tumor performed by CARIS test

  Involved signaling pathway          Test                        Method   Result
  ----------------------------------- --------------------------- -------- --------------------
  Tyrosine kinase surface receptors   EGFR expression             IHC      Positive
                                      EGFR mutation               NGS      Negative
                                      c-met expression            IHC      Negative
                                      c-met mutation              NGS      Negative
                                      Her2neu expression          IHC      Negative
                                      Her2neu amplification       CISH     Negative
                                      Her2neu mutation            NGS      Negative
  RAS/RAF/MEK                         HRAS, KRAS, NRAS mutation   NGS      Negative
                                      BRAF mutational analysis    NGS      Negative
  PI3K/AKT/mTOR                       PIK3CA mutation             NGS      *Exon 9/E542K* Mut
                                      AKT1 mutation               NGS      Negative
                                      AKT1 expression             IHC      Negative
                                      PTEN expression             IHC      Positive
                                      PTEN mutation               NGS      Negative
  Immune checkpoint                   PD-1 expression             IHC      Negative
                                      PD-L1 expression            IHC      Negative
  Apoptosis                           P53                         NGS      *Exon 5/C176S* Mut

**Abbreviations:** CISH, chromogenic in situ hybridization; IHC, immunohistochemistry; NGS, next-generation sequencing; Mut, mutant.
